Phenomenon and Business Essence

At the 93rd CMEF exhibition, brain-computer interfaces moved from the lab to the exhibition floor—this wasn't a technology showcase, this was a commercial positioning signal. Xiangyu Medical, Vishee Medical, and Brainsons appearing together signals that leading companies have entered the "final sprint before product approval." The projected scale of China's brain-computer interface market exceeds 200 billion yuan by 2030, while fewer than 10 companies can currently deliver clinical-grade products. The window period is closing.

Analogous Dimension: This is the 1998 Cardiac Stent Moment

In the late 1990s, coronary stents moved from the lab to the catheterization lab, with Medtronic and Boston Scientific completing the transition from "new technology" to "surgical standard" in five years, while traditional open-heart surgery equipment manufacturers were almost completely routed. Core logic for the analogy: Brain-computer interfaces similarly depend on a three-step leap: "regulatory approval → hospital procurement → medical insurance coverage." Once the first batch of products enters the medical insurance catalog, the market will complete structural reshaping in 18-36 months, and latecomers will pay not R&D costs, but a market entry premium tax.

Industry Shakeout and Endgame Projection

Applying Grove's "strategic inflection point" framework: Winners are companies with existing NMPA filing paths (Brainsons, Shentian Technology, etc.) and platform companies offering integrated "brain-computer interface + rehabilitation training" solutions. Outsiders are small-to-medium device manufacturers relying solely on traditional EMG and transcranial magnetic stimulation equipment for revenue—once brain-computer interface products enter top-tier hospital procurement lists, their products will be replaced rather than coexist. Timeline: Around 2026 for the first large-scale approvals, market structure essentially locked by 2028.

High-Risk Zones

  • Regional agents with annual revenues below 50 million yuan and sole dependency on neurorehabilitation devices
  • Medical device distributors without R&D pipelines, purely reliant on channels
  • Equipment manufacturers yet to establish clinical partnerships with neurology departments at top-tier hospitals

Two Paths Forward for Executives

Path One (Offensive): Immediately sign exclusive regional distribution agreements with 1-2 brain-computer interface companies holding NMPA filing qualifications. Initial investment approximately 500,000-2 million yuan (deposit + training + clinical promotion), exchanging this for first-mover channel advantages after 2026 approval.

Path Two (Defensive): Before the brain-computer interface impact arrives, concentrate抽取现有神经康复器械业务的利润，向non-directly competing sectors (such as surgical robot consumables, AI imaging-assisted diagnosis) to shift resources. Complete product line transition within 2 years, loss prevention as priority.